Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 4 versus SERPASIL ESIDRIX 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 4 versus SERPASIL ESIDRIX 2.
METATENSIN #4 vs SERPASIL-ESIDRIX #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
None Documented
None Documented
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination